Review Article

Therapeutic Drugs in Bone Loss-Associated Disorders: Clinical Outcomes and Challenges

Author(s): Daniela M. Sousa, Ines S. Alencastre, Luís Leitao, Estrela Neto, Cecilia J. Alves and Meriem Lamghari

Volume 18, Issue 6, 2017

Page: [696 - 704] Pages: 9

DOI: 10.2174/1389450117666160709024547

Price: $65

Open Access Journals Promotions 2
Abstract

Current therapeutic drugs for the treatment of bone loss-associated disorders such as osteoporosis and metastatic bone disease have limited clinical outcomes, namely in terms of efficiency and sustainability. Given the ageing of population in developed countries and the cumulative costs with treatment, bone loss-associated disorders represent a major socioeconomic burden worldwide. In this review, the therapeutic agents targeting bone loss tested in clinical and pre-clinical trials are summarized, as well as the challenges encountered by clinicians and patients. In an effort to attain costeffective clinical outcomes, potential cellular and signalling targets are disclosed.

Keywords: Bone loss, therapy, anabolic agents, anti-resorptive agents, clinical trials, osteoclasts, osteoblasts.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy